iVexSol

IVexSol is a manufacturer and developer of the vector. It offers its flagship intelligent transformative platform for developing lentiviral vector cell lines. Developer of a platform for the production of vectors. Operating in the Life Sciences > Life Sciences Platforms and Tools, Life Sciences > Genomics sector. with business models spanning Genomics > Enabling Technologies > Technology Platforms > Gene Delivery, Life Sciences Platforms and Tools > Research Services > Diversified. Founded in 2018, headquartered in Toronto, Canada. The company has raised $39.0M at the Series A stage, backed by investors including Massachusetts Life Sciences Center, Bristol-Myers Squibb, Charles River Laboratories, Asahi Kasei, Casdin Capital.